Kojima S, Inoue I, Hirata Y, Kimura G, Saito F, Kawano Y, Satani M, Ito K, Omae T
Nephron. 1987;46(1):45-8. doi: 10.1159/000184295.
Plasma concentrations of immunoreactive (IR)-atrial natriuretic polypeptide (ANP) were measured before and after hemodialysis (HD) as well as isolated ultrafiltration (UF) in 9 patients with end-stage renal disease. There were significant falls in plasma concentrations of IR-ANP during both UF (from 78.6 +/- 109.7 to 45.4 +/- 56.8 pg/ml; mean +/- SD; p less than 0.025) and HDs (from 84.7 +/- 48.6 to 35.0 +/- 28.4 (p less than 0.01) on first HD; from 73.7 +/- 74.2 to 31.8 +/- 21.8 pg/ml (p less than 0.01) on later HD). There were distinct positive correlations between blood pressures and plasma concentrations of IR-ANP. These results support the view that ANP is secreted mainly by the expansion of blood volume. The fall in plasma concentrations of IR-ANP after HD seems to be caused by the decrease of blood volume, but not by removal due to dialysis of the peptide. However, the physiological role of ANP in patients with end-stage renal disease remains unknown.
对9例终末期肾病患者在血液透析(HD)以及单纯超滤(UF)前后测量了免疫反应性(IR)心房利钠多肽(ANP)的血浆浓度。在超滤期间(从78.6±109.7降至45.4±56.8 pg/ml;均值±标准差;p<0.025)以及血液透析期间(首次血液透析时从84.7±48.6降至35.0±28.4(p<0.01);后续血液透析时从73.7±74.2降至31.8±21.8 pg/ml(p<0.01)),IR-ANP的血浆浓度均显著下降。血压与IR-ANP的血浆浓度之间存在明显的正相关。这些结果支持了ANP主要由血容量扩张分泌的观点。血液透析后IR-ANP血浆浓度的下降似乎是由血容量减少引起的,而非由于该肽的透析清除。然而,ANP在终末期肾病患者中的生理作用仍不清楚。